An updated review of teriflunomide's use in multiple sclerosis.
Neurodegener Dis Manag
; 11(5): 387-409, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1394696
ABSTRACT
Teriflunomide, a once daily, oral disease-modifying therapy, has demonstrated consistent efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis (MS) and with a first clinical episode suggestive of MS treated up to 12 years. This review is an update to a previous version that examined data from the teriflunomide core clinical development program and extension studies. Data have since become available from active comparator trials with other disease-modifying therapies, treatment-related changes in brain volume (analyzed using structural image evaluation using normalization of atrophy) and real-world evidence including patient-reported outcomes. Initial data on the potential antiviral effects of teriflunomide in patients with MS, including case reports of patients infected with the 2019 novel coronavirus (SARS-CoV-2), are also presented.
Lay abstract Teriflunomide, a treatment taken orally once a day, has shown consistent effectiveness and safety in patients with relapsing forms of multiple sclerosis (MS). This review is an update to a previous version that summarized the trials from when teriflunomide was in clinical development for MS. Some of the newer studies described here compared teriflunomide with other MS treatments. Studies have shown positive effects of teriflunomide on brain volume; teriflunomide may also be effective against some viruses. People taking teriflunomide generally report stable cognition and quality of life, with no worsening of fatigue or disability. In the EU, teriflunomide has been recently approved for use in pediatric patients 10 years of age and above.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Toluidines
/
Crotonates
/
Multiple Sclerosis, Relapsing-Remitting
/
Hydroxybutyrates
/
Immunosuppressive Agents
/
Nitriles
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Neurodegener Dis Manag
Year:
2021
Document Type:
Article
Affiliation country:
Nmt-2021-0014
Similar
MEDLINE
...
LILACS
LIS